Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Harvard Business School
Johnson and Johnson
Merck
Moodys

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,263,600

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 8,263,600 protect, and when does it expire?

Patent 8,263,600 protects NOXAFIL and is included in one NDA.

This patent has twenty-four patent family members in seventeen countries.

Summary for Patent: 8,263,600
Title:Antifungal composition with enhanced bioavailability
Abstract: A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: ##STR00001## at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.
Inventor(s): Sharpe; Stefan (Jersey City, NJ), Sequeira; Joel (Edison, NJ), Harris; David (New Providence, NJ), Mahashabde; Shashank (Kendall Park, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/161,097
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,263,600
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,263,600

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Schering NOXAFIL posaconazole SUSPENSION;ORAL 022003-001 Sep 15, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,263,600

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033096   Start Trial
Australia 2002257104   Start Trial
Australia 2006200354   Start Trial
Brazil 0208626   Start Trial
Canada 2443089   Start Trial
China 100415234   Start Trial
China 1499930   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Mallinckrodt
Medtronic
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.